Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Healthy pullback from a major move is healthy.
CUBT has Verified Profile designation on OTC Markets.
The company is not late on their filing until August 17.
Meanwhile, I am getting tempted to buy more in the .o8's again.
It is amusing to see there is a presumption that an therapeutic for Dry AMD using eyedrops vs. injections that may not improve vision is (but slows down the progression of vision loss) not competitive with an injectable for Wet AMD.
From Outlook Therapeutics PR:
The NORSE TWO pivotal Phase 3 clinical trial enrolled a total of 228 subjects with wet AMD across 39 clinical trial sites in the United States. Participants in the trial were treated for 12 months. The primary endpoint for the study was the proportion of patients who gain at least 15 letters in the best corrected visual acuity (BCVA) at 11 months. The trial compared ONS-5010 dosed monthly to LUCENTIS®, which was dosed as one of the regimens listed in the LUCENTIS® label (i.e., patients were treated monthly for the first three months followed by less frequent dosing; the PIER regimen). The key secondary endpoint for NORSE TWO was the mean change in the BCVA through 11 months.
------
LUCENTIS® is an already approved and huge revenue generator--yet Outlook Therapeutics is in trials to see if they can prove that their therapeutic is an improvement on a drug already on the market.
In the case of CUBT, the IND for Metformin (not the spelling here)eye drops is too prove efficacy (initially) for stopping the progression of Dry AMD. Initial approval would proving that out. Longer trials may result in a reversal of vision loss to Dry AMD...but not necessary for CUBT to be VERY successful for an indication of DRY AMD therapy to slow disease progression.
Overpaid CEO's are often red flags in the microcap world.
Looks like investors want to see a buyout of VIAC and not just a Go It ALONE strategy.
I like to say that I rent stocks. lol
Nice timing on that buy.
SHORT INTEREST 7,460,859 as of 07/15/2021 Up almost 4 million shares shorted from June 30 to July 15.
07/15/2021 7,460,859 1
06/30/2021 3,683,364
Comcast CEO said today that they see no need for more streaming assets.
If they are real pumpers, they pump when there is no news.
There is no news, so they are silent.
Guess that means that...hmmm.
If there is a Form 10 filing, and/or a CEO blog post and/or a partnership announced for a clinical trial and/or another license agreement for another patent from the NIH or wherever, I am sure there will be some more activity here.
(BTW,last post was off topic, which is why it disappeared. Wrong stock symbol and/or board.)
ELTP has been a losing investment for years--unless you traded it.
There were some nice breakouts over the years--but if you believed in a future, you lost.
VERB is putting together an interesting company that will get attention. imo. It will take time to see it in the numbers, it it will come.
News of a merger is \probably the only hing that is going to get VIAC going again.
Bet it is more imminent than it was when he said it. LOL
Their IP portfolio would be very important to an acquirer.
Smelling a short squeeze here. Cha Ching..
Yes, your message is clear. There is much to be done by CUBT to advance their business plan. ANd that s why we are a $0.10 and not at $1.00 right now.
Not unlike many small biotechs, you have to build a management team, obtain funding, attract joint venture partners, design clinical trials, recruit patients, announce trial results, attend biotech conferences, uplist to higher exchanges (OTCQB,NASDAQ etc.) etc.
And each of the above are potential news catalysts that will have an effect on the stock price.
And they look like they are getting their news out globally now
www.onlinebeststor.com/curative-biotechnology-inc-names-marc-drimer-cpa-to-board-of-directors/
www. heymuse.com/curative-biotechnology-inc-names-marc-drimer-cpa-to-board-of-directors/
www.icrowdpt.com/2021/07/20/biotecnologia-curativa-inc-nomeia-marc-drimer-cpa-para-conselho-de-administracao/
www.icrowdru.com/2021/07/20/curative-biotechnology-inc-?????????-?????-???????-cpa-?-?????/
www.icrowdsp.com/2021/07/20/curative-biotechnology-inc-nombra-a-marc-drimer-cpa-a-la-junta-directiva/
www.bignewsnetwork.com/news/270375720/curative-biotechnology-inc-names-marc-drimer-cpa-to-board-of-directors
www.canadatousd.com/curative-biotechnology-inc-names-marc-drimer-cpa-to-board-of-directors/
But you might want to look at Bristol Myers as a less risky investment. They already have revenue, net income, have patented products on the market etc.
Unfortunately, there is about a ZERO chance to see a 500% gain in the price of Bristol Myers in the next six months like I wouldnot be surprised to see here.
GLTU
That chart IS a Five Year MONTHLY Chart.
I understand that it looks bad--but each candle is a month.
Looks like they issued the most recent press release internationally too. And to some websites I usually do not see.
www.ipsnews.net/business/2021/07/20/curative-biotechnology-inc-names-marc-drimer-cpa-to-board-of-directors/
www.reportedtimes.com/curative-biotechnology-inc-names-marc-drimer-cpa-to-boa
Looks like they are getting wider distribution. Friend of mine in Europe (Germany) saw the PR auf Deutsch in a German financial PR site.
What is the next "expected" piece of news for MRKR?
Have they recruited a new Medical Officer yet?
It is the patented delivery of metformin directly into the eye in the form of eye drops that differentiates CUBT's approach vs. the other modalities.
If anything, I would be more concerned if NO ONE was looking into metformin and AMD.
Thanks for sharing
Due Diligence on a Scientific Advisory Board member of CUBT
Kapil Bharti, PhD
Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH
Dr. Kapil Bharti obtained his Ph.D. from J.W. Goethe University, Frankfurt, Germany, graduating summa cum laude. His Ph.D. work involved research in the areas of heat stress, chaperones, and epigenetics. He did his postdoc at the National Institutes of Health, where he published numerous papers in the areas of transcription regulation, pigment cell biology, and developmental biology of the eye. His lab at the National Eye Institute recently received approval for the first U.S. phase I/IIa trial to test autologous iPSC-derived RPE patch in AMD patients. He has given several keynote lectures, won several awards including being the first Earl Stadtman Tenure Track Investigator at NEI, NIH Directors award and NEI Directors Dr. Karl Kupfer Visionary award for his revolutionary work on developing ocular cell-therapies, and serves on the advisory board of several companies and patient-advocacy groups. His current work as a Senior Investigator at NEI involves understanding mechanism of retinal degenerative diseases using induced pluripotent stem cell derived eye cells and tissues, and developing cell-based and drug-based therapies for such diseases.
Affiliation:
Kapil Bharti
Senior Investigator
National Eye Institute
National Institutes of Health
Bethesda, MD 20892
https://worldmedicalinnovation.org/speakers/kapil-bharti-phd/
The EYES have it!
For the record, if you ever experience a price spike like this one, get OUT of a large part of your position and suppress that Greed germ we all get infected with. Sell at different prices...but get out of some.
PS-- I would say they same thing about CUBT if it spiked to $1.10 in three days like EYES did.
Speculation and risk is part of the landscape with every biotech. Especially microcap biotechs which have the greatest risk and greatest profit potential.
Selected biotech charts
The obvious message lies within the charts above. ONPH and ANVS were speculations when they were trading at the lower prices. They are still speculations and the higher prices.
Rumors ARE guesses in microcap land. LOL